시장보고서
상품코드
1676856

의료용 혈액투석여과기 시장 : 휴대성별, 구성요소별, 모드별, 최종사용자별 - 세계 예측(2025-2030년)

Medical Hemodiafiltration Machine Market by Portability, Components, Modes, End User - Global Forecast 2025-2030

발행일: | 리서치사: 360iResearch | 페이지 정보: 영문 195 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

의료용 혈액투석여과기 시장은 2024년 8억 6,684만 달러에서 2025년에는 9억 2,656만 달러로 연평균 7.00%의 CAGR로 성장하여 2030년에는 13억 113만 달러에 달할 것으로 예상됩니다.

주요 시장 통계
기준 연도 2024년 8억 6,684만 달러
추정 연도 2025년 9억 2,656만 달러
예측 연도 2030년 13억 113만 달러
CAGR(%) 7.00%

지난 10년간 의료 현장은 신장 치료 기술의 패러다임 변화를 목격해 왔으며, 혈액투석여과기의 진화가 그 증거입니다. 만성콩팥병의 유병률이 증가하고 환자 중심의 치료법이 점점 더 중요해지는 가운데, 최신 혈액투석여과기는 치료의 정확성을 높이고 환자의 예후를 개선하는 데 있어 기본이 되고 있습니다. 이 소개에서는 만성 신장 질환의 치료를 재정의한 기술적 진보, 임상적 효과, 혁신적인 디자인 요소의 통합을 추적하면서 시장 환경에 대한 자세한 개요를 설명합니다.

새로운 연구는 혈액 내 독소를 안전하고 효과적으로 제거하기 위해 첨단 여과 시스템의 중요한 역할을 강조하고 있습니다. 제조업체들은 현재 정밀 의료와 환자 맞춤형 치료의 시대에 힘입어 내구성, 운영 효율성 및 임상 결과에 중점을 두고 있습니다. 이 보고서는 엔지니어링의 발전과 투석 의료 프로세스에 대한 이해도가 높아짐에 따라 전 세계 환자 관리 전략에 어떤 변화를 가져올 수 있는지에 대해 설명합니다.

또한, 빠르게 성장하는 사용자층과 투석기의 장점에 대한 인식이 높아지면서 의료 서비스 제공자들은 최첨단 솔루션에 대한 투자를 늘리고 있습니다. 기술 혁신과 임상 검증의 상호 작용은 기존 수요를 충족시킬 뿐만 아니라 미래의 의료 수요를 예측할 수 있는 시장을 형성하고 있습니다. 임상연구가 혈액투석여과에 대한 이점을 지속적으로 검증하는 가운데, 설계 및 제조에서 의료서비스 제공에 이르는 가치사슬 전반의 이해관계자들은 환자 치료 강화, 합병증 감소, 치료 프로토콜 최적화를 실현할 수 있는 기회를 얻게 되었습니다.

의료용 혈액투석여과기 시장의 변화

최근 몇 년 동안 의료용 혈액투석여과의 상황은 기술의 비약적인 발전, 역동적인 규제 환경의 변화, 환자 치료 모델의 진화로 인해 크게 변화하고 있습니다. 외과의사, 신장 전문의, 생의학 엔지니어들이 힘을 합쳐 기존 임상 기준을 뛰어넘을 뿐만 아니라 휴대성 향상과 혁신적인 액체 처리 메커니즘과 같은 새로운 변수를 도입한 장치를 개발하고 있습니다.

임상 기관은 운영 안정성 향상에서 환자 안전 조치 개선에 이르기까지 혈액투석여과기에 최첨단 기능을 통합하는 것의 이점을 인식하고 있습니다. 실시간 모니터링 및 자동 보정을 포함한 기술 통합은 서비스 프로토콜과 유지보수 요법을 재정의하고, 다운타임을 줄여 치료를 더 빨리 제공할 수 있도록 돕습니다. 또한, 구성요소의 소형화에 중점을 두어 휴대용 시스템의 길을 열어 원격지 및 재택의료 환경에서도 투석을 실현 가능한 옵션으로 만들었습니다.

이러한 디자인의 진화는 의료의 개인화라는 보다 광범위한 산업 트렌드를 반영하고 있습니다. 끊임없는 기술 혁신은 환자의 당면한 요구를 충족시킬 뿐만 아니라 미래의 치료 패러다임의 변화를 예측하고 있습니다. 연구기관, 기술 개발자, 임상 최종사용자 간의 공동 개발이 기술 혁신의 속도를 가속화하고 시장을 지속가능한 성장으로 이끌고 있습니다. 궁극적으로 이러한 혁신적 변화는 의료 서비스 제공자가 현재와 미래의 환자 수요를 충족시킬 수 있는 충분한 역량을 갖출 수 있도록 업계를 재편할 것입니다.

혈액투석여과기 시장 주요 세분화 인사이트

세분화 분석은 제품 개발 및 시장 역학에 영향을 미치는 몇 가지 중요한 기준에 주목하여 시장을 다각도로 파악합니다. 주요 측면 중 하나는 휴대성을 면밀히 조사하여 환자에게 이동성과 유연성을 제공하는 휴대용 혈액투석여과기와 엄격하게 통제된 임상 환경을 위해 특별히 설계된 고정식 혈액투석여과기를 구분하는 것입니다. 이러한 접근 방식은 다양한 환자군과 의료 환경의 다양한 요구와 사용 패턴을 강조합니다.

또 다른 통찰력 있는 세분화는 시스템의 주요 구성요소에 대한 인사이트입니다. 혈액 펌프, 투석기 유닛, 혈액투석 필터에 대한 평가를 통해 이해관계자들은 각 모듈 내의 기술적 과제와 기회를 이해할 수 있었습니다. 이 컴포넌트 기반 렌즈는 유지보수 전략에 도움이 될 뿐만 아니라, 기술 업그레이드가 성능과 임상 결과를 개선할 수 있는 가능성을 시사합니다.

시장은 또한 중간 희석, 후희석, 전희석 접근 방식을 고려하여 작동 모드에 따라 제품을 차별화하고 있습니다. 각 모드마다 고유 한 장점과 적응 문제가 있기 때문에 제조업체는 특정 임상 프로토콜 및 환자 요구 사항에 맞게 기계를 조정할 수 있습니다. 마지막으로, 학술 및 연구 기관, 투석 클리닉, 재택의료 환경 및 병원에 걸친 최종사용자 분석을 통해 중요한 인사이트를 얻었습니다. 이러한 세분화를 통해 각 사용자 그룹의 미묘한 선호도가 드러났으며, 치료 환경의 변화에 대한 새로운 트렌드도 발견되었습니다. 전반적으로, 이러한 세분화 인사이트는 시장을 발전시키는 데 필수적인 특정 수요와 혁신적 기회를 이해하는 데 도움이 될 것입니다.

목차

제1장 서문

제2장 조사 방법

제3장 주요 요약

제4장 시장 개요

제5장 시장 인사이트

  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 과제
  • 시장 세분화 분석
  • Porter's Five Forces 분석
  • PESTEL 분석
    • 정치
    • 경제
    • 사회
    • 기술
    • 법률
    • 환경

제6장 의료용 혈액투석여과기 시장 : 휴대성별

  • 휴대용 혈액투석여과기
  • 고정형 혈액투석여과기

제7장 의료용 혈액투석여과기 시장 : 구성요소별

  • 혈액 펌프
  • 투석 유닛
  • 혈액투석필터

제8장 의료용 혈액투석여과기 시장 : 모드별

  • 중간 희석 HDF
  • 희석 후 HDF
  • 전 희석 HDF

제9장 의료용 혈액투석여과기 시장 : 최종사용자별

  • 학술연구기관
  • 투석 클리닉
  • 재택 케어 환경
  • 병원

제10장 아메리카의 의료용 혈액투석여과기 시장

  • 아르헨티나
  • 브라질
  • 캐나다
  • 멕시코
  • 미국

제11장 아시아태평양의 의료용 혈액투석여과기 시장

  • 호주
  • 중국
  • 인도
  • 인도네시아
  • 일본
  • 말레이시아
  • 필리핀
  • 싱가포르
  • 한국
  • 대만
  • 태국
  • 베트남

제12장 유럽, 중동 및 아프리카의 의료용 혈액투석여과기 시장

  • 덴마크
  • 이집트
  • 핀란드
  • 프랑스
  • 독일
  • 이스라엘
  • 이탈리아
  • 네덜란드
  • 나이지리아
  • 노르웨이
  • 폴란드
  • 카타르
  • 러시아
  • 사우디아라비아
  • 남아프리카공화국
  • 스페인
  • 스웨덴
  • 스위스
  • 터키
  • 아랍에미리트
  • 영국

제13장 경쟁 구도

  • 시장 점유율 분석, 2024
  • FPNV 포지셔닝 매트릭스, 2024
  • 경쟁 시나리오 분석
  • 전략 분석과 제안

기업 리스트

  • ARI Medical Technology Co., Ltd.
  • Asahi Kasei Corporation
  • AWAK Technologies Pte. Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • DaVita Inc.
  • Diality, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Guangzhou MeCan Medical Limited
  • Infomed SA
  • JMS Co. Ltd.
  • Kalstein
  • KNS MEDICAL SAS
  • Medtronic PLC
  • Mozarc Medical Holding LLC
  • Nephro Care India Limited
  • Nikkiso Co., Ltd.
  • Nipro Corporation
  • Outset Medical, Inc.
  • Quanta Dialysis Technologies Ltd.
  • Rockwell Medical, Inc.
  • Shenzhen Landwind Industry Co., Ltd.
  • Soxa Formulations & Research(Pvt.) Ltd.
  • SWS Hemodialysis Care Co., Ltd.
  • Toray Industries, Inc.
  • Wesley Biotech Co., Ltd.
ksm 25.03.25

The Medical Hemodiafiltration Machine Market was valued at USD 866.84 million in 2024 and is projected to grow to USD 926.56 million in 2025, with a CAGR of 7.00%, reaching USD 1,301.13 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 866.84 million
Estimated Year [2025] USD 926.56 million
Forecast Year [2030] USD 1,301.13 million
CAGR (%) 7.00%

The medical landscape has witnessed a paradigm shift in renal care technology over the past decade, and the evolution of hemodiafiltration machines stands as a testament to this transformation. With rising incidences of chronic kidney disease and an increasing emphasis on patient-centric therapeutic modalities, modern hemodiafiltration devices have become fundamental to offering enhanced treatment accuracy and improved patient outcomes. This introduction provides an in-depth overview of the market environment, tracing technological advancements, clinical efficacy, and the integration of innovative design elements that have redefined chronic kidney care.

Emerging research has highlighted the vital role that advanced filtration systems play in ensuring the safe and effective removal of toxins from the bloodstream. Manufacturers are now focusing on durability, operational efficiency, and clinical outcomes, driven by an era that demands precision medicine and adaptive, patient-specific therapies. This report unearths how the combination of engineering advancements and an increased understanding of dialysis care processes promises to revolutionize patient management strategies all around the globe.

Furthermore, the rapidly expanding user base and heightened awareness about the benefits of these machines have encouraged healthcare providers to invest in state-of-the-art solutions. The interplay between technical innovation and clinical validation has fostered a marketplace that not only caters to the existing demand but also anticipates future health care needs. As clinical studies continue to validate the benefits of hemodiafiltration, stakeholders across the value chain-from design and production to healthcare provision-are presented with a unique opportunity to enhance patient care, reduce complications, and optimize treatment protocols.

Transformative Shifts in the Medical Hemodiafiltration Landscape

Recent years have seen transformative shifts in the medical hemodiafiltration landscape, driven by a confluence of technological breakthroughs, dynamic regulatory changes, and evolving patient care models. Surgeons, nephrologists, and biomedical engineers have come together to develop machines that not only surpass previous clinical benchmarks but also introduce new variables such as enhanced portability and innovative fluid handling mechanisms.

Clinical institutions are increasingly acknowledging the benefits of integrating state-of-the-art features into hemodiafiltration machines, ranging from increased operational reliability to improved patient safety measures. Technological integration, including real-time monitoring and automated calibration, has redefined service protocols and maintenance regimens, thereby reducing downtime and expediting the delivery of treatment. Moreover, a heightened focus on the miniaturization of components has paved the way for portable systems, making dialysis a feasible option even in remote or home care settings.

This evolution in design reflects a broader industry trend towards personalization in medical treatment. Continuous innovation not only addresses the immediate needs of patients but also anticipates future shifts in treatment paradigms. Collaboration among research institutions, technology developers, and clinical end users has accelerated the pace of innovation, positioning the market for sustained growth. Ultimately, these transformative shifts are reshaping the industry, ensuring that healthcare providers are well-equipped to meet both current and future patient demands.

Key Segmentation Insights in the Hemodiafiltration Machine Market

The segmentation analysis offers a multidimensional view of the market by looking at several critical criteria that influence product development and market dynamics. One major dimension scrutinizes portability, differentiating between portable hemodiafiltration machines that empower patients with mobility and flexibility, and their stationary counterparts specifically designed for tightly controlled clinical environments. This approach highlights the disparate needs and usage patterns across various patient demographics and healthcare settings.

Another insightful segmentation considers the key components of the systems. The evaluation of blood pumps, dialyzer units, and hemodiafilters has allowed stakeholders to understand technical challenges and opportunities within each module. This component-based lens not only informs maintenance strategies but also hints at where technical upgrades could lead to improved performance and clinical outcomes.

The market also differentiates products based on modes of operation, considering mid-dilution, postdilution, and predilution approaches. Each mode presents its own distinct benefits and adaptation challenges, thus offering manufacturers a pathway to tailor their machines to the specific clinical protocols and patient requirements. Lastly, critical insights have been drawn from the end user analysis, which extends across academic and research institutes, dialysis clinics, home care settings, and hospitals. This segmentation reveals the nuanced preferences of each user group while simultaneously pointing to the emerging trends in treatment environment shifts. Overall, these segmentation insights help in understanding the specific demands and innovative opportunities essential for driving the market forward.

Based on Portability, market is studied across Portable Hemodiafiltration Machines and Stationary Hemodiafiltration Machines.

Based on Components, market is studied across Blood Pumps, Dialyzer Units, and Hemodiafilter.

Based on Modes, market is studied across Mid-dilution HDF, Postdilution HDF, and Predilution HDF.

Based on End User, market is studied across Academic & Research Institutes, Dialysis Clinics, Home Care Settings, and Hospitals.

Key Regional Insights on the Hemodiafiltration Machine Market

An evaluation of the global market reveals distinct regional insights that emphasize dynamic growth opportunities and the influence of healthcare infrastructure on the adoption of hemodiafiltration machines. In the Americas, robust research initiatives, coupled with high healthcare spending and progressive adoption of patient-centered care models, set the stage for rapid market expansion. Meanwhile, regions encompassing Europe, the Middle East & Africa offer a compelling blend of mature health systems and emerging markets, creating a fertile ground for innovations driven by combined public and private investments in healthcare technology.

In Asia-Pacific, accelerating urbanization and a steadily increasing prevalence of chronic conditions are catalyzing demand. This region is characterized by a mix of state-driven healthcare reforms and private sector innovation, which is instrumental in shaping product offerings and market distribution channels. Regional economic and demographic peculiarities intertwine to form unique market dynamics, with each region demanding bespoke strategies to address local challenges and opportunities. These insights underscore the importance of regional customization in product development and market strategy to harness steady growth across diverse geographical landscapes.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping the Hemodiafiltration Landscape

The competitive landscape in the hemodiafiltration machine segment is defined by a host of companies that bring both legacy and innovation to the fore. Prominent players such as ARI Medical Technology Co., Ltd. and Asahi Kasei Corporation lead the charge in product innovation, combining extensive research capabilities with robust engineering expertise. AWAK Technologies Pte. Ltd. and B. Braun Melsungen AG have further cemented their positions by delivering reliable solutions that enhance patient outcomes. Baxter International Inc. and DaVita Inc. are renowned for integrating comprehensive patient care approaches into their offerings, making significant strides in clinical efficacy and operational efficiency.

Other notable names include Diality, Inc. and Fresenius Medical Care AG & Co. KGaA, which emphasize continuous improvement and technological evolution. Guangzhou MeCan Medical Limited and Infomed SA have effectively bridged the gap between advanced research and practical application, while JMS Co., Ltd. and Kalstein contribute to the market with specialized expertise. KNS MEDICAL SAS and Medtronic PLC stand out as pioneers who are relentlessly pushing the boundaries of innovation in device design, and Mozarc Medical Holding LLC, along with Nephro Care India Limited, have gained respect for their commitment to quality and local market adaptability.

Furthermore, industry trailblazers such as Nikkiso Co., Ltd. and Nipro Corporation have leveraged deep clinical insights to refine their product portfolios, and Outset Medical, Inc. along with Quanta Dialysis Technologies Ltd. are recognized for their forward-thinking approaches in technology integration. Rockwell Medical, Inc. and Shenzhen Landwind Industry Co., Ltd. have carved out significant market niches by focusing on reliability and efficiency, while Soxa Formulations & Research(Pvt.) Ltd., SWS Hemodialysis Care Co., Ltd., Toray Industries, Inc., and Wesley Biotech Co., Ltd. continue to drive competitive excellence with specialized solutions tailored to diverse clinical environments. Together, these companies not only define current market trends but also serve as catalysts for future innovation and enhanced patient care.

The report delves into recent significant developments in the Medical Hemodiafiltration Machine Market, highlighting leading vendors and their innovative profiles. These include ARI Medical Technology Co., Ltd., Asahi Kasei Corporation, AWAK Technologies Pte. Ltd., B. Braun Melsungen AG, Baxter International Inc., DaVita Inc., Diality, Inc., Fresenius Medical Care AG & Co. KGaA, Guangzhou MeCan Medical Limited, Infomed SA, JMS Co. Ltd., Kalstein, KNS MEDICAL SAS, Medtronic PLC, Mozarc Medical Holding LLC, Nephro Care India Limited, Nikkiso Co., Ltd., Nipro Corporation, Outset Medical, Inc., Quanta Dialysis Technologies Ltd., Rockwell Medical, Inc., Shenzhen Landwind Industry Co., Ltd., Soxa Formulations & Research(Pvt.) Ltd., SWS Hemodialysis Care Co., Ltd., Toray Industries, Inc., and Wesley Biotech Co., Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to adopt a multifaceted strategic approach that leverages technological innovations, robust clinical studies, and market-specific segmentation insights to advance their market positioning. Leaders should prioritize investing in R&D to drive the creation of more portable and efficient devices, while concurrently enhancing existing systems by integrating components that significantly improve patient safety and treatment efficacy.

It is prudent to develop flexible product lines that cater to diverse end user frameworks, ensuring that trends observed across academic, clinical, and home care settings are addressed through modular design improvements. Performance optimization through iterative testing and collaboration with clinical experts is essential. Furthermore, forging strategic partnerships with regional stakeholders will help in navigating local regulatory frameworks and in tailoring offerings to the unique dynamics of each market. Embracing digital transformation technologies for remote monitoring and predictive maintenance can also greatly enhance operational efficiencies, driving long-term leadership in the sector.

Conclusion: Charting a Future of Innovation and Excellence

In conclusion, the medical hemodiafiltration machine market stands at the intersection of technological innovation and evolving clinical practice. The dynamic landscape shaped by scalable segmentation, rapid technological advancements, and deep regional insights paves the way for a future replete with transformative opportunities. Stakeholders now have the mandate to adopt forward-thinking strategies that address the multifaceted challenges of chronic kidney disease management. By focusing on technological integration, component optimization, and targeted market segmentation, industry leaders can streamline operations and drive superior patient outcomes.

Ultimately, the road ahead hinges on the ability of manufacturers and healthcare providers to innovate continually, scale their solutions globally, and maintain a clear focus on patient-centric care. A cohesive, strategic approach that capitalizes on cutting-edge research and strategic regional positioning is essential to not only meet current demands but to future-proof the industry in an era characterized by constant innovation and evolving healthcare needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising awareness about the benefits of hemodiafiltration over traditional dialysis treatments
      • 5.1.1.2. Growing aging population necessitating advanced renal care solutions
      • 5.1.1.3. Rising prevalence of chronic kidney diseases increasing the need for hemodiafiltration
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with machine reliability and technical issues impacting the adoption of hemodiafiltration
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments in R&D for the integration of IoT and smart technology within dialysis systems
      • 5.1.3.2. Innovations in hemodiafiltration machine for personalized and home-based dialysis options
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with regulatory compliance and certification of medical hemodiafiltration machines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Portability: Increasing utilization of portable hemodiafiltration machines owing to their flexible and convenient treatment options
    • 5.2.2. End User: Growing adoption of hemodiafiltration machines by dialysis clinics owing to their need for high-volume, efficient, and patient-specific treatment capabilities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Medical Hemodiafiltration Machine Market, by Portability

  • 6.1. Introduction
  • 6.2. Portable Hemodiafiltration Machines
  • 6.3. Stationary Hemodiafiltration Machines

7. Medical Hemodiafiltration Machine Market, by Components

  • 7.1. Introduction
  • 7.2. Blood Pumps
  • 7.3. Dialyzer Units
  • 7.4. Hemodiafilter

8. Medical Hemodiafiltration Machine Market, by Modes

  • 8.1. Introduction
  • 8.2. Mid-dilution HDF
  • 8.3. Postdilution HDF
  • 8.4. Predilution HDF

9. Medical Hemodiafiltration Machine Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Dialysis Clinics
  • 9.4. Home Care Settings
  • 9.5. Hospitals

10. Americas Medical Hemodiafiltration Machine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Medical Hemodiafiltration Machine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Medical Hemodiafiltration Machine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA clearance for Quanta's high-flow home hemodialysis system signifies a shift in ESRD care focus towards home treatment
    • 13.3.2. Nephro Care India Limited and NIT Silchar collaborate on cost-effective AI-enabled smart haemodialysis machine to address shortfall in renal care
    • 13.3.3. Fresenius Medical Care advances U.S. dialysis options with FDA-cleared hemodiafiltration technology
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ARI Medical Technology Co., Ltd.
  • 2. Asahi Kasei Corporation
  • 3. AWAK Technologies Pte. Ltd.
  • 4. B. Braun Melsungen AG
  • 5. Baxter International Inc.
  • 6. DaVita Inc.
  • 7. Diality, Inc.
  • 8. Fresenius Medical Care AG & Co. KGaA
  • 9. Guangzhou MeCan Medical Limited
  • 10. Infomed SA
  • 11. JMS Co. Ltd.
  • 12. Kalstein
  • 13. KNS MEDICAL SAS
  • 14. Medtronic PLC
  • 15. Mozarc Medical Holding LLC
  • 16. Nephro Care India Limited
  • 17. Nikkiso Co., Ltd.
  • 18. Nipro Corporation
  • 19. Outset Medical, Inc.
  • 20. Quanta Dialysis Technologies Ltd.
  • 21. Rockwell Medical, Inc.
  • 22. Shenzhen Landwind Industry Co., Ltd.
  • 23. Soxa Formulations & Research(Pvt.) Ltd.
  • 24. SWS Hemodialysis Care Co., Ltd.
  • 25. Toray Industries, Inc.
  • 26. Wesley Biotech Co., Ltd.
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제